Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2012

View Archived Issues

Scientists at Actelion Pharmaceuticals patent new FPR2/ALX receptor agonists

New MPGES-1 inhibitors designed in Germany

New long-acting drug is well tolerated as once-weekly growth hormone replacement therapy

PARP-1/2 inhibitor shows promising safety profile in patients with cancer

Lupin presents novel GLP-1 receptor modulators

New agents for cancer reported by Kasina Laila Innova Pharmaceuticals

First-in-human study of EP-100 complete

Ampio Pharmaceticals discloses data from Optina trial

Novel DPP IV inhibitors prepared

OncoSec launches new phase II OMS ElectroImmunotherapy trial

DNAzyme is effective in models of skin cancer

FDA grants priority review for Xarelto applications

Proteostasis Therapeutics discloses novel prosteostasis regulators

ACT clear to proceed with dry AMD trial

Repros reaches agreement with FDA on pivotal Androxal studies

Titan Pharmaceuticals completes study of nonfluctuating dopamine receptor agonist drug

Lux Biosciences completes enrollment in phase III trial in noninfectious uveitis

TONIX reports encouraging pharmacokinetic data on TNX-102

Potential biomarker of AMD identified

Acusphere gives update on MAA for Imagify

FDA places clinical hold on IB-1001 trials

Pergamum reports topline data from phase II trial in prevention of postsurgical adhesions

Sanofi withdraws MAA for anticoagulant drug

Phase III Halaven study in new breast cancer indication does not meet primary endpoints

Xiaflex approved in Canada

Norwegian government awards grant to Bionor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...